Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myelin Oligodendrocyte Glycoprotein (MOG)
- Target
- MOG
- Molecular classification
- Type I transmembrane protein, Glycoprotein, Immunoglobulin superfamily member
01
Overview
Myelin oligodendrocyte glycoprotein (MOG) is a CNS-specific glycoprotein expressed on the surface of oligodendrocytes and the outermost layer of myelin sheaths. It plays a role in myelin structure and integrity, and is a major target of autoantibodies in autoimmune demyelinating diseases like MS, NMOSD and ADEM. Detection of anti-MOG antibodies is diagnostically relevant. While MOG knockout mice do not show severe phenotypes under normal conditions, its role as an autoantigen makes it a key therapeutic target for interventions aimed at preventing or treating demyelinating diseases.
- Other names
- MOG proteinMyelin-oligodendrocyte glycoprotein
02
Mechanism of action
Target of autoantibodies, leading to complement-mediated demyelination and oligodendrocyte damage. Antibody therapies targeting immune cells involved in MOG-Ab production may be used.
03
Biological functions
Cell adhesionMyelin sheath structural integrityImmune modulationAutoantigen presentationMicrotubule regulation
04
Disease associations
Multiple sclerosis (MS)Neuromyelitis optica spectrum disorders (NMOSD)MOG antibody-associated disease (MOGAD)Acute disseminated encephalomyelitis (ADEM)Optic neuritisAutoimmune demyelination
05
Safety considerations
Immunosuppression related to therapeutic targeting of immune cellsPotential for off-target effects of antibody therapiesRedundancy/compensation among CNS proteins may limit therapeutic efficacy
06
Biomarkers
Anti-MOG antibodies in serum or CSF
Beyond the preview
Go deeper on Myelin Oligodendrocyte Glycoprotein (MOG).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myelin Oligodendrocyte Glycoprotein (MOG).